Article
The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates.
Antimicrobial agents and chemotherapy - 1 Jul 2003
Diallo Karidia, Brenner Bluma, Oliveira Maureen, Moisi Daniela, Detorio Mervi, Götte Matthias, Wainberg Mark A
Abstract excerpt
The M184V substitution in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), encoding high-level resistance to lamivudine (3TC), results in decreased HIV-1 replicative capacity, diminished RT processivity, and increased RT fidelity in biochemical assays. We assessed the effect of M184V on the development of resistance to the nonnucleoside RT inhibitors efavirenz (EFV) and nevirapine, and to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.